메뉴 건너뛰기




Volumn 17, Issue 1, 2018, Pages

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: A randomised controlled trial

Author keywords

Magnetic resonance imaging; SGLT 2 inhibition; Tissue sodium content; Type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; PLACEBO; SODIUM; SODIUM GLUCOSE COTRANSPORTER 2; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN;

EID: 85042484963     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-017-0654-z     Document Type: Article
Times cited : (153)

References (41)
  • 1
    • 84859513088 scopus 로고    scopus 로고
    • Salt and hypertension: is salt dietary reduction worth the effort?
    • Frisoli TM, Schmieder RE, Grodzicki T, Messerli FH. Salt and hypertension: is salt dietary reduction worth the effort? Am J Med. 2012;125(5):433-9
    • (2012) Am J Med , vol.125 , Issue.5 , pp. 433-439
    • Frisoli, T.M.1    Schmieder, R.E.2    Grodzicki, T.3    Messerli, F.H.4
  • 4
    • 84980320178 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
    • Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-72
    • (2016) Circulation , vol.134 , Issue.10 , pp. 752-772
    • Heerspink, H.J.1    Perkins, B.A.2    Fitchett, D.H.3    Husain, M.4    Cherney, D.Z.5
  • 5
    • 84994853573 scopus 로고    scopus 로고
    • Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medicatio
    • Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension (Dallas, Tex: 1979). 2016;68(6):1355-64
    • (2016) Hypertension (Dallas, Tex: 1979) , vol.68 , Issue.6 , pp. 1355-1364
    • Mancia, G.1    Cannon, C.P.2    Tikkanen, I.3    Zeller, C.4    Ley, L.5    Woerle, H.J.6    Broedl, U.C.7    Johansen, O.E.8
  • 6
    • 84994476908 scopus 로고    scopus 로고
    • Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure
    • Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016;12:393-405
    • (2016) Vasc Health Risk Manag , vol.12 , pp. 393-405
    • Reed, J.W.1
  • 7
    • 84996551945 scopus 로고    scopus 로고
    • Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes
    • Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Exp Opin Drug Metab Toxicol. 2016;13:211-23
    • (2016) Exp Opin Drug Metab Toxicol , vol.13 , pp. 211-223
    • Tomlinson, B.1    Hu, M.2    Zhang, Y.3    Chan, P.4    Liu, Z.M.5
  • 8
    • 85015765803 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
    • Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016;37(42):3192-200
    • (2016) Eur Heart J , vol.37 , Issue.42 , pp. 3192-3200
    • Marx, N.1    McGuire, D.K.2
  • 9
    • 84928382328 scopus 로고    scopus 로고
    • Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?
    • Lovshin JA, Gilbert RE. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective? Curr Hypertens Rep. 2015;17(6):551
    • (2015) Curr Hypertens Rep , vol.17 , Issue.6 , pp. 551
    • Lovshin, J.A.1    Gilbert, R.E.2
  • 10
    • 67349275999 scopus 로고    scopus 로고
    • Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
    • Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513-9
    • (2009) Clin Pharmacol Ther , vol.85 , Issue.5 , pp. 513-519
    • Komoroski, B.1    Vachharajani, N.2    Feng, Y.3    Li, L.4    Kornhauser, D.5    Pfister, M.6
  • 13
    • 84883432973 scopus 로고    scopus 로고
    • Biomedical applications of sodium MRI in vivo
    • Madelin G, Regatte RR. Biomedical applications of sodium MRI in vivo. J Magn Reson Imaging JMRI. 2013;38(3):511-29
    • (2013) J Magn Reson Imaging JMRI , vol.38 , Issue.3 , pp. 511-529
    • Madelin, G.1    Regatte, R.R.2
  • 16
    • 66749106368 scopus 로고    scopus 로고
    • Macrophages regulate saltdependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism
    • Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park JK, Beck FX, Muller DN, Derer W, et al. Macrophages regulate saltdependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med. 2009;15(5):545-52
    • (2009) Nat Med , vol.15 , Issue.5 , pp. 545-552
    • Machnik, A.1    Neuhofer, W.2    Jantsch, J.3    Dahlmann, A.4    Tammela, T.5    Machura, K.6    Park, J.K.7    Beck, F.X.8    Muller, D.N.9    Derer, W.10
  • 17
    • 77149143546 scopus 로고    scopus 로고
    • Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rat
    • Machnik A, Dahlmann A, Kopp C, Goss J, Wagner H, van Rooijen N, Eckardt KU, Muller DN, Park JK, Luft FC, et al. Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rats. Hypertension (Dallas, Tex: 1979). 2010;55(3):755-61
    • (2010) Hypertension (Dallas, Tex: 1979) , vol.55 , Issue.3 , pp. 755-761
    • Machnik, A.1    Dahlmann, A.2    Kopp, C.3    Goss, J.4    Wagner, H.5    van Rooijen, N.6    Eckardt, K.U.7    Muller, D.N.8    Park, J.K.9    Luft, F.C.10
  • 18
    • 84895484977 scopus 로고    scopus 로고
    • Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
    • Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. DiabetesMetab Res Rev. 2014;30(3):204-21
    • (2014) DiabetesMetab Res Rev , vol.30 , Issue.3 , pp. 204-221
    • Zhang, M.1    Zhang, L.2    Wu, B.3    Song, H.4    An, Z.5    Li, S.6
  • 19
    • 85013827882 scopus 로고    scopus 로고
    • A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
    • Ott C, Jumar A, Striepe K, Friedrich S, Karg MV, Bramlage P, Schmieder RE. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16(1):26
    • (2017) Cardiovasc Diabetol , vol.16 , Issue.1 , pp. 26
    • Ott, C.1    Jumar, A.2    Striepe, K.3    Friedrich, S.4    Karg, M.V.5    Bramlage, P.6    Schmieder, R.E.7
  • 21
    • 0023724346 scopus 로고
    • Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group
    • Rose G, Stamler J, Stamler R, Elliott P, Marmot M, Pyorala K, Kesteloot H, Joossens J, Hansson L, Mancia G, Dyer A. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. BMJ Clin Res ed. 1988;297(6644):319-28
    • (1988) BMJ Clin Res ed , vol.297 , Issue.6644 , pp. 319-328
    • Rose, G.1    Stamler, J.2    Stamler, R.3    Elliott, P.4    Marmot, M.5    Pyorala, K.6    Kesteloot, H.7    Joossens, J.8    Hansson, L.9    Mancia, G.10    Dyer, A.11
  • 22
    • 85010202013 scopus 로고    scopus 로고
    • Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
    • Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16(1):8
    • (2017) Cardiovasc Diabetol , vol.16 , Issue.1 , pp. 8
    • Hayashi, T.1    Fukui, T.2    Nakanishi, N.3    Yamamoto, S.4    Tomoyasu, M.5    Osamura, A.6    Ohara, M.7    Yamamoto, T.8    Ito, Y.9    Hirano, T.10
  • 23
    • 85033772700 scopus 로고    scopus 로고
    • Correction to: dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
    • Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Correction to: dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16(1):149
    • (2017) Cardiovasc Diabetol , vol.16 , Issue.1 , pp. 149
    • Hayashi, T.1    Fukui, T.2    Nakanishi, N.3    Yamamoto, S.4    Tomoyasu, M.5    Osamura, A.6    Ohara, M.7    Yamamoto, T.8    Ito, Y.9    Hirano, T.10
  • 25
    • 84943187885 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
    • Imprialos KP, Sarafidis PA, Karagiannis AI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens. 2015;33(11):2185-97
    • (2015) J Hypertens , vol.33 , Issue.11 , pp. 2185-2197
    • Imprialos, K.P.1    Sarafidis, P.A.2    Karagiannis, A.I.3
  • 26
    • 85021710250 scopus 로고    scopus 로고
    • Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
    • Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, Hirose T. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16(1):84
    • (2017) Cardiovasc Diabetol , vol.16 , Issue.1 , pp. 84
    • Shigiyama, F.1    Kumashiro, N.2    Miyagi, M.3    Ikehara, K.4    Kanda, E.5    Uchino, H.6    Hirose, T.7
  • 27
    • 85031924469 scopus 로고    scopus 로고
    • Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
    • Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, Bruno RM. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16(1):138
    • (2017) Cardiovasc Diabetol , vol.16 , Issue.1 , pp. 138
    • Solini, A.1    Giannini, L.2    Seghieri, M.3    Vitolo, E.4    Taddei, S.5    Ghiadoni, L.6    Bruno, R.M.7
  • 28
    • 84995684231 scopus 로고    scopus 로고
    • Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
    • Scheerer MF, Rist R, Proske O, Meng A, Kostev K. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Diabetes Metab Syndr Obes Targets Ther. 2016;9:337-45
    • (2016) Diabetes Metab Syndr Obes Targets Ther , vol.9 , pp. 337-345
    • Scheerer, M.F.1    Rist, R.2    Proske, O.3    Meng, A.4    Kostev, K.5
  • 29
    • 85028958040 scopus 로고    scopus 로고
    • Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study
    • Persson F, Nystrom T, Jorgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13077
    • (2017) Diabetes Obes Metab
    • Persson, F.1    Nystrom, T.2    Jorgensen, M.E.3    Carstensen, B.4    Gulseth, H.L.5    Thuresson, M.6    Fenici, P.7    Nathanson, D.8    Eriksson, J.W.9    Norhammar, A.10
  • 33
    • 0026035348 scopus 로고
    • Central role of sodium in hypertension in diabetic subjects
    • Weidmann P, Ferrari P. Central role of sodium in hypertension in diabetic subjects. Diabetes Care. 1991;14(3):220-32
    • (1991) Diabetes Care , vol.14 , Issue.3 , pp. 220-232
    • Weidmann, P.1    Ferrari, P.2
  • 34
    • 0022160189 scopus 로고
    • Pressor factors and responsiveness in hypertension accompanying diabetes mellitu
    • Weidmann P, Beretta-Piccoli C, Trost BN. Pressor factors and responsiveness in hypertension accompanying diabetes mellitus. Hypertension (Dallas, Tex: 1979). 1985;7(6 Pt 2):Ii33-42
    • (1985) Hypertension (Dallas, Tex: 1979) , vol.7 , Issue.6 , pp. Ii33-Ii42
    • Weidmann, P.1    Beretta-Piccoli, C.2    Trost, B.N.3
  • 35
    • 84880850027 scopus 로고    scopus 로고
    • Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
    • Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853-62
    • (2013) Diabetes Obes Metab , vol.15 , Issue.9 , pp. 853-862
    • Lambers Heerspink, H.J.1    de Zeeuw, D.2    Wie, L.3    Leslie, B.4    List, J.5
  • 38
    • 0023680030 scopus 로고
    • Dietary salt intake. A determinant of cardiac involvement in essential hypertension
    • Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD. Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation. 1988;78(4):951-6
    • (1988) Circulation , vol.78 , Issue.4 , pp. 951-956
    • Schmieder, R.E.1    Messerli, F.H.2    Garavaglia, G.E.3    Nunez, B.D.4
  • 39
    • 84894058295 scopus 로고    scopus 로고
    • Measurement techniques for magnetic resonance imaging of fast relaxing nuclei
    • Konstandin S, Nagel AM. Measurement techniques for magnetic resonance imaging of fast relaxing nuclei. Magma (New York, NY). 2014;27(1):5-19
    • (2014) Magma (New York, NY) , vol.27 , Issue.1 , pp. 5-19
    • Konstandin, S.1    Nagel, A.M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.